Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Request to FDA to Extend Comment Period for Proposed Rule on Regulation of LDTs
-
ACMG Comments on CY 2024 Physician Fee Schedule Proposed Rule
-
Stakeholder Letter Calling for Physician Payment Legislation Based on MEI
-
Sign-on Letter Opposing Updated VALID Act & ACM Exemption
-
Sign-on Letter Asking Congress to Address Instability of the Medicare Physician Payment System
-
Sign-on Letter to Congressional Leadership Concerning the VALID Act
-
ACMG Comments on FDA Draft Guidance for Products Incorporating Genome Editing
-
Group Sign-on Letter Concerning the VALID Act of 2022 Discussion Draft
-
ACMG Response to Opposing Inclusion of the VALID Act in the FDASLA Act
-
Amicus Brief for PP v MT (MT SC) – Access to Reproductive Healthcare